|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
DE3681787D1
(de)
|
1985-07-05 |
1991-11-07 |
Whitehead Biomedical Inst |
Expression von fremdem genetischem material in epithelzellen.
|
|
US4863457A
(en)
|
1986-11-24 |
1989-09-05 |
Lee David A |
Drug delivery device
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
HK1008049A1
(en)
|
1987-09-11 |
1999-04-30 |
Whitehead Institute For Biomedical Research |
Transduced fibroblasts and use therefor
|
|
ATE110108T1
(de)
|
1987-12-11 |
1994-09-15 |
Whitehead Biomedical Inst |
Genetische modifizierung von endothelialen zellen.
|
|
DE68927996T2
(de)
|
1988-02-05 |
1997-12-04 |
Hughes Howard Med Inst |
Modifizierte hepatozyten und deren anwendung
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
|
DE69123981T3
(de)
|
1990-10-31 |
2006-06-14 |
Cell Genesys Inc |
Nützliche retrovirale vektoren für die gentherapie
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
US5721348A
(en)
|
1990-12-14 |
1998-02-24 |
University Of Connecticut |
DNA encoding PH-20 proteins
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
WO1994002559A1
(en)
|
1992-07-23 |
1994-02-03 |
Minnesota Mining And Manufacturing Company |
Shaped abrasive particles and method of making same
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
DE69334275D1
(de)
|
1992-08-21 |
2009-05-20 |
Univ Bruxelles |
Immunoglobuline ohne Leichtkette
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
IT1265573B1
(it)
|
1993-09-17 |
1996-11-22 |
Zanussi Grandi Impianti Spa |
Forno di cottura di alimenti con porta perfezionata
|
|
US5308341A
(en)
|
1993-09-28 |
1994-05-03 |
Becton, Dickinson And Company |
Method of testing the dose accuracy of a medication delivery device
|
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
|
DE69535897D1
(de)
|
1994-03-07 |
2009-01-22 |
Nektar Therapeutics |
Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
|
EP0859841B1
(en)
|
1995-08-18 |
2002-06-19 |
MorphoSys AG |
Protein/(poly)peptide libraries
|
|
US5773019A
(en)
|
1995-09-27 |
1998-06-30 |
The University Of Kentucky Research Foundation |
Implantable controlled release device to deliver drugs directly to an internal portion of the body
|
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US6001329A
(en)
|
1996-05-06 |
1999-12-14 |
Uab Research Foundation |
Radiolabeled fusion toxins for cancer therapy
|
|
US6146361A
(en)
|
1996-09-26 |
2000-11-14 |
Becton Dickinson And Company |
Medication delivery pen having a 31 gauge needle
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
GB9626960D0
(en)
|
1996-12-27 |
1997-02-12 |
Glaxo Group Ltd |
Valve for aerosol container
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6096872A
(en)
|
1997-10-14 |
2000-08-01 |
Ortho Diagnostic Systems, Inc. |
Viral clearance process
|
|
US5954047A
(en)
|
1997-10-17 |
1999-09-21 |
Systemic Pulmonary Development, Ltd. |
Methods and apparatus for delivering aerosolized medication
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6302855B1
(en)
|
1998-05-20 |
2001-10-16 |
Novo Nordisk A/S |
Medical apparatus for use by a patient for medical self treatment of diabetes
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
AU779869B2
(en)
|
1999-04-13 |
2005-02-17 |
Nektar Therapeutics |
Pulmonary administration of dry powder formulations for treating infertility
|
|
WO2000061178A1
(en)
|
1999-04-13 |
2000-10-19 |
Inhale Therapeutics Systems, Inc. |
Pulmonary administration of dry powder formulations for treating infertility
|
|
US6192891B1
(en)
|
1999-04-26 |
2001-02-27 |
Becton Dickinson And Company |
Integrated system including medication delivery pen, blood monitoring device, and lancer
|
|
GB9910975D0
(en)
|
1999-05-13 |
1999-07-14 |
Univ Strathclyde |
Rapid dehydration of proteins
|
|
US6277099B1
(en)
|
1999-08-06 |
2001-08-21 |
Becton, Dickinson And Company |
Medication delivery pen
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
WO2002013859A1
(en)
|
2000-08-10 |
2002-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method of inhibiting antibody-containing solution from coagulating or becoming turbid
|
|
ATE547080T1
(de)
|
2000-08-30 |
2012-03-15 |
Univ Johns Hopkins |
Vorrichtungen zur intraokularen arzneimittelabgabe
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
JP4383168B2
(ja)
|
2001-09-12 |
2009-12-16 |
ベクトン・ディキンソン・アンド・カンパニー |
マイクロ針投与デバイスおよび薬物投与デバイス
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
AU2003256266A1
(en)
|
2002-06-12 |
2003-12-31 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
|
EP1545611B1
(en)
|
2002-09-06 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
US20040102469A1
(en)
|
2002-09-13 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for reducing the mortality rate
|
|
GB0222023D0
(en)
|
2002-09-21 |
2002-10-30 |
Aventis Pharma Ltd |
Inhaler
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
FR2849436B1
(fr)
|
2002-12-27 |
2007-01-05 |
Patrick Frayssinet |
Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
|
|
WO2004073551A2
(en)
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
EP2330213A1
(en)
|
2003-03-05 |
2011-06-08 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
|
US20050054048A1
(en)
|
2003-07-29 |
2005-03-10 |
Luigi Grasso |
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
GB0416328D0
(en)
|
2004-07-21 |
2004-08-25 |
Univ Cardiff |
Use of dry powder compositions for pulmonary delivery
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006094234A1
(en)
|
2005-03-03 |
2006-09-08 |
Xencor, Inc. |
Methods for the design of libraries of protein variants
|
|
AU2006230413B8
(en)
|
2005-03-31 |
2011-01-20 |
Xencor, Inc |
Fc variants with optimized properties
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
JP5405122B2
(ja)
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
低粘度のタンパク質製剤およびその用途
|
|
BRPI0708424A2
(pt)
|
2006-03-02 |
2011-05-31 |
Alexion Pharma Inc |
prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
|
|
HUE066795T2
(hu)
|
2006-03-15 |
2024-09-28 |
Alexion Pharma Inc |
Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
|
|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
US8037880B2
(en)
|
2006-04-07 |
2011-10-18 |
The University Of Western Ontario |
Dry powder inhaler
|
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
|
EP2064335A4
(en)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
CA2690382A1
(en)
|
2007-06-14 |
2008-12-24 |
Biogen Idec Ma Inc. |
Antibody formulations
|
|
CA2693771A1
(en)
|
2007-07-13 |
2009-01-22 |
Abbott Biotechnology Ltd. |
Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
AU2009303526B2
(en)
|
2008-10-14 |
2015-01-15 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
JP6223659B2
(ja)
|
2008-11-10 |
2017-11-01 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体関連障害を処置するための方法および組成物
|
|
AU2015227544B2
(en)
|
2008-11-10 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
|
US20120282654A1
(en)
|
2009-04-29 |
2012-11-08 |
Schering Corporation |
Antibody purification
|
|
WO2010138918A1
(en)
|
2009-05-29 |
2010-12-02 |
Pacira Pharmaceuticals, Inc. |
Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
|
|
NZ597259A
(en)
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
SI3409289T1
(sl)
|
2010-02-26 |
2020-12-31 |
Novo Nordisk A/S |
Stabilni sestavki, ki vsebujejo protitelo
|
|
NZ602220A
(en)
|
2010-03-11 |
2014-10-31 |
Rinat Neuroscience Corp |
Antibodies with ph dependent antigen binding
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
CA2798120A1
(en)
|
2010-04-30 |
2011-11-03 |
Paul P. Tamburini |
Antibodies having reduced immunogenicity in a human
|
|
AU2011245117B2
(en)
|
2010-04-30 |
2015-03-12 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for using the antibodies
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
EP2698431B1
(en)
|
2011-03-30 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
CA2871934C
(en)
|
2012-04-30 |
2023-06-13 |
Medimmune, Llc |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
JP6113455B2
(ja)
|
2012-10-12 |
2017-04-12 |
日野自動車株式会社 |
車載用電力制御装置の冷却システム及びその異常診断方法
|
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
JP5878270B2
(ja)
|
2012-12-19 |
2016-03-08 |
プロメラス， エルエルシー |
高純度ノルボルネンアルカノールおよびその誘導体の製造方法
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
NZ711451A
(en)
*
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
EP3236772A4
(en)
|
2014-12-22 |
2018-10-17 |
Alexion Pharmaceuticals, Inc. |
Methods of purifying recombinant proteins
|
|
WO2016160756A2
(en)
|
2015-03-31 |
2016-10-06 |
Alexion Pharmaceuticlas, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents
|
|
US20180311299A1
(en)
|
2015-05-01 |
2018-11-01 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
WO2016209956A1
(en)
|
2015-06-26 |
2016-12-29 |
Alexion Pharmaceuticals, Inc. |
A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
|
WO2017012636A1
(en)
|
2015-07-17 |
2017-01-26 |
Heiko Schwertner |
Device for the integrated collection of kinetic, photonic and thermal energy
|
|
EP3328885A1
(en)
|
2015-09-11 |
2018-06-06 |
Bruce Andrien |
Recombinant glycosylated eculizumab and eculizumab variants
|
|
CN108025072A
(zh)
|
2015-09-22 |
2018-05-11 |
辉瑞公司 |
制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂
|
|
EP3368073B1
(en)
|
2015-10-30 |
2024-05-15 |
Alexion Pharmaceuticals, Inc. |
A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
|
|
KR20260070290A
(ko)
|
2015-12-16 |
2026-05-18 |
유씨비 홀딩스 인코포레이티드 |
보체 활성의 조절인자
|
|
US20170182242A1
(en)
|
2015-12-27 |
2017-06-29 |
Abbvie Inc. |
Wearable Automatic Injection Device and Related Methods of Use
|
|
US20190023775A1
(en)
|
2016-01-11 |
2019-01-24 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
|
IL263481B2
(en)
|
2016-06-14 |
2024-06-01 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
JP7256741B2
(ja)
|
2016-10-12 |
2023-04-12 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
|
|
AU2017376884B2
(en)
|
2016-12-16 |
2024-10-03 |
Samsung Bioepis Co., Ltd |
Stable aqueous anti-C5 antibody composition
|
|
TWI828672B
(zh)
|
2017-01-31 |
2024-01-11 |
日商中外製藥股份有限公司 |
用於治療或預防c5相關疾病的醫藥組合物以及治療或預防c5相關疾病的方法
|
|
IL307197B2
(en)
|
2017-07-11 |
2026-03-01 |
Alexion Pharma Inc |
Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
|
|
ES2965486T3
(es)
|
2017-07-27 |
2024-04-15 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-C5 de alta concentración
|
|
WO2019032374A1
(en)
|
2017-08-10 |
2019-02-14 |
West Pharma, Services Il, Ltd. |
INJECTOR DELAYED CARTRIDGE PUNCHING MECHANISM
|
|
CA3078631A1
(en)
|
2017-10-11 |
2019-04-18 |
Jacob M. Waugh |
Methods and compositions for topical delivery
|
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
EP3802603A1
(en)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃ５抗体の産生方法
|
|
WO2020092546A1
(en)
|
2018-10-30 |
2020-05-07 |
Alexion Pharmaceuticals, Inc. |
Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
|
|
US12240893B2
(en)
|
2018-10-30 |
2025-03-04 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
|
|
JP7511566B2
(ja)
|
2019-01-25 |
2024-07-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与
|
|
US11642470B2
(en)
|
2019-02-11 |
2023-05-09 |
West Pharma. Services IL, Ltd. |
Anti-C5 antibody dispensing injector and method of injection
|
|
JP2023501377A
(ja)
|
2019-11-08 |
2023-01-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
高濃度抗ｃ５抗体配合物
|
|
US20230416344A1
(en)
|
2020-04-16 |
2023-12-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating a complement mediated disorder caused by viruses
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|
|
WO2022011086A1
(en)
|
2020-07-09 |
2022-01-13 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
CA3173016A1
(en)
|
2021-01-22 |
2022-07-28 |
Gin-Fu CHEN |
Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
|
|
MX2023015073A
(es)
|
2021-06-14 |
2024-01-18 |
Alexion Pharma Inc |
Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la dermatomiositis (dm).
|